Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04995887 · ClinicalTrials.gov registry record
RUBY Post-Market Registry on the Jada® System
A clinical trial, sponsored by Alydia Health.
- Completed
- Registry status
- 809
- Enrollment target
NCT04995887: Completed study, sponsored by Alydia Health.
NCT04995887 is a clinical trial that has completed, run by Alydia Health. The registered enrollment target is 809 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04995887 has completed, sponsored by Alydia Health.
- COMPLETED
- Registry status
- 809 participants
- Enrollment target
Study Summary
The RUBY Study is a multicenter, observational, post-market registry designed to collect observational data on patients treated with the Jada System in the post-market setting.
Primary Outcome
Proportion of patients with atony-related abnormal postpartum uterine bleeding or PPH successfully treated with the Jada System. Treatment success is defined as the avoidance of escalated non-surgical or surgical intervention to control abnormal postpartum uterine bleeding or PPH after the Jada System was used. Note: Concomitant treatment with uterotonics or uterine compression sutures does not constitute escalation (i.e., failure). However, if the Jada treatment was aborted to instead administ
Interventions
- DEVICE Jada® System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2022-04-30 |
What the finished NCT04995887 record still lists
NCT04995887 is an observational study that tracks outcomes without assigning an intervention. The registered 809 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Jada® System is the first listed.
NCT04995887 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04995887 about?
NCT04995887 is a clinical study titled "RUBY Post-Market Registry on the Jada® System". The RUBY Study is a multicenter, observational, post-market registry designed to collect observational data on patients treated with the Jada System in the post-market setting.
What is the current status of trial NCT04995887?
This trial is currently completed. The enrollment target is 809 participants. The study started on 2020-10-01. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT04995887?
The interventions under investigation include: Jada® System (DEVICE).
Who is sponsoring clinical trial NCT04995887?
This trial is sponsored by Alydia Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI